Skip to Main Content

Paper Details

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
J Immunother Cancer
36
2021
Author NameAffiliation
Carlos E de AndreaUniversity of Navarra
Carlos E de AndreaUniversity Clinic of Navarra
  • 1 - 2

Datasets

Release 1.2